Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av MACI hos pasienter i alderen 10 til 17 år med symptomatiske kondrale eller osteokondrale defekter i kneet (PEAK)

30. oktober 2026 oppdatert av: Vericel Corporation

En prospektiv, åpen, randomisert, samtidig aktiv kontrollert, longitudinell, multisenter, fase 3 klinisk studie av sikkerheten og effekten av MACI hos pasienter i alderen 10 til 17 år med symptomatiske kondrale eller osteokondrale defekter i kneet på grunn av osteochondritis dissekan. Akutt traume

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Studieoversikt

Detaljert beskrivelse

This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 participants, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).

After meeting screening criteria at the initial visit, all participants will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, participants will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All participants who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible participants will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Participants randomized to microfracture will undergo the procedure during the screening arthroscopy.

All biopsied tissue will be sent to the Vericel manufacturing facility in Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from participants randomized to the MACI group will be used in the preparation of the MACI implant; cells from participants randomized to the microfracture group will be cryopreserved.

Participants randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Participants are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.

Participants will be followed post-study treatment for 2 years (104 Weeks).

Studietype

Intervensjonell

Registrering (Antatt)

45

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Palo Alto, California, Forente stater, 94304
        • Rekruttering
        • Stanford University School of Medicine
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kevin Shea
      • Sacramento, California, Forente stater, 95817
        • Rekruttering
        • Shriners Hospital for Children Northern California
        • Hovedetterforsker:
          • Brian Haus
        • Ta kontakt med:
      • Sacramento, California, Forente stater, 95817
        • Rekruttering
        • University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
        • Hovedetterforsker:
          • Brian Haus
        • Ta kontakt med:
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70121
        • Rekruttering
        • Ochsner Health System-Elmwood
        • Ta kontakt med:
        • Hovedetterforsker:
          • Brian Godshaw
    • Maryland
      • Baltimore, Maryland, Forente stater, 21224
        • Rekruttering
        • Johns Hopkins Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rushyuan Jay Lee
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48106
        • Rekruttering
        • University of Michigan Medsport Orthopaedic Surgery
        • Ta kontakt med:
        • Hovedetterforsker:
          • Eileen Crawford
    • New York
      • The Bronx, New York, Forente stater, 10467
        • Fullført
        • Montefiore Medical Center/Albert Einstein College of Medicine
    • Ohio
      • Akron, Ohio, Forente stater, 44308
        • Rekruttering
        • Akron Children's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • John Polousky
      • Columbus, Ohio, Forente stater, 43202
        • Rekruttering
        • The Ohio State University Jameson Crane Sports Medicine Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Christopher Kaeding
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Penn Medicine University City
        • Ta kontakt med:
        • Hovedetterforsker:
          • James Carey
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
        • Ta kontakt med:
        • Hovedetterforsker:
          • Theodore Ganley
    • Rhode Island
      • East Providence, Rhode Island, Forente stater, 02914
        • Rekruttering
        • University Orthopedics, Inc.
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nicholas Lemme
    • Texas
      • Houston, Texas, Forente stater, 77094
        • Fullført
        • Texas' Children Hospital
      • Plano, Texas, Forente stater, 75024
        • Fullført
        • Children's Medical Center Plano
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53201
        • Rekruttering
        • Children's Hospital of Wisconsin
        • Ta kontakt med:
        • Hovedetterforsker:
          • John Erickson

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

10 år til 17 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 10 to 17 years at the time of planned randomization

  • Symptomatic cartilage or osteochondral defects

  • One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).

    1. Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
    2. Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
  • At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.

  • Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.

  • Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.

  • Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.

  • Written informed consent

Exclusion Criteria:

  • Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)

  • Previous investigational drug or device use within 3 months prior to Screening

  • Avascular necrosis of the target knee (other than potential OCD lesion to be treated)

  • Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate

  • ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion

  • Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)

  • Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint

  • Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)

  • Known history of septic arthritis in the index knee joint

  • Current malignancy or treatment for malignancy within the past 5 years

  • Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin

  • Females who are pregnant or lactating

  • Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:

    • Any condition that has potential for negatively impacting intra or postoperative course
    • Conditions that limit compliance with rehabilitation program
    • Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
    • Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
    • Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: MACI

autologous cultured chondrocytes on porcine collagen membrane

autologous cultured chondrocytes on porcine collagen membrane

Annen: microfracture

surgical procedure

Arthroscopic microfracture treatment

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
Tidsramme: Baseline and Week 104

A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 104

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in KOOS-Child subscores
Tidsramme: Baseline and Week 104

The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 104
Change from Baseline in KOOS-Child subscores
Tidsramme: Baseline and Week 52

The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 52

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Treatment Emergent Adverse Events
Tidsramme: Week 104

A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

Week 104

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Jonathan Hopper, BSc (Hons), MB ChB, FRCSEd, Vericel Corporation

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. oktober 2018

Primær fullføring (Antatt)

1. februar 2030

Studiet fullført (Antatt)

1. februar 2030

Datoer for studieregistrering

Først innsendt

4. april 2018

Først innsendt som oppfylte QC-kriteriene

15. juli 2018

Først lagt ut (Faktiske)

17. juli 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere